

European Antibiotics Market by Drug Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Opportunity Analysis and Industry Forecast, 2019–2027

https://marketpublishers.com/r/E47218FB49D6EN.html

Date: February 2021

Pages: 181

Price: US\$ 6,168.00 (Single User License)

ID: E47218FB49D6EN

Abstracts

The European antibiotics market was valued at \$11,561 million in 2019, and is projected to reach \$13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.

Antibiotics is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections but not viral infections. Antibiotics are the medications that either stop bacteria from growing or kill bacteria, directly referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics, easily available at the drug store and in the hospital with a prescription or without a prescription in most of the countries. Antibiotics are used during transplants, dialysis, suppressed immune system, joint replacement, and others.

There is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination



therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The European antibiotics market is segmented on the basis of class, drug origin, spectrum of activity, route of administration, and region. By class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, Carbapenem, and Monobactam. By drug origin, the market is categorized into natural, semisynthetic, and synthetic. By spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By route of administration, the market is divided into oral, intravenous, and others.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the European Antibiotics Market along with the current trends and future estimations to elucidate the imminent investment pockets.

The report provides a quantitative analysis for the period of 2019–2027 to enable stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the market by components helps to understand the various types of instruments used across geographies.

Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these regions.

Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the market.

Extensive analysis of the market is conducted by closely following key product positioning, and monitoring the top contenders within the market framework.



KEY MARKET SEGMENTS

Bv	Drua	Class
-	2.09	01000

KEY WARKET SEGMENTS		
By Drug Class		
Beta Lactam and Beta Lactamase Inhibitors		
Penicillin		
Cephalosporin		
Carbapenem		
Monobactam		
Quinolone		
Macrolide		
Others		
By Drug Origin		
Natural		
Semisynthetic		
Synthetic		
By Spectrum of Activity		
Broad-spectrum Antibiotic		


В

Broad-spectrum Antibiotic

Narrow-spectrum Antibiotic

By Route of Administration







Pfizer Inc.

Sanofi S.A.



Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
- 1.3.1. List of key players profiled in the report
- 1.4. Research methodology
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. Key findings of the study
- 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top investment pockets
 - 3.2.2. Top winning strategies
- 3.3. Top player positioning, 2019
- 3.4. Porter's five forces analysis
- 3.5. Market dynamics
 - 3.5.1. Drivers
 - 3.5.1.1. Rise in prevalence of infectious diseases
- 3.5.1.2. Development of novel approaches for new antibiotics for treating bacterial infections
 - 3.5.2. Restraints
 - 3.5.2.1. Development of antibiotic resistance
 - 3.5.2.2. The time taken for the regulatory approval
 - 3.5.3. Opportunities
- 3.5.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.
 - 3.5.4. Impact analysis
- 3.6. Impact of COVID-19 on European Antibiotic Market



CHAPTER 4: EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS

- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Beta Lactam and Beta Lactamase Inhibitors
- 4.2.1. Key market trends, growth factors, and opportunities
- 4.2.2. Market analysis, by country
- 4.2.3. Market size and forecast, by type
 - 4.2.3.1. Penicillin
 - 4.2.3.1.1. Market size and forecast
 - 4.2.3.2. Cephalosporin
 - 4.2.3.2.1. Market size and forecast
 - 4.2.3.3. Carbapenem
 - 4.2.3.3.1. Market size and forecast
 - 4.2.3.4. Monobactam
 - 4.2.3.4.1. Market size and forecast
- 4.3. Quinolone
 - 4.3.1. Key market trends, growth factors, and opportunities
 - 4.3.2. Market analysis, by country
- 4.4. Macrolide
 - 4.4.1. Key market trends, growth factors, and opportunities
 - 4.4.2. Market analysis, by country
- 4.5. Other
 - 4.5.1. Key market trends, growth factors, and opportunities
 - 4.5.2. Market analysis, by country

CHAPTER 5: EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN

- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. Natural
 - 5.2.1. Market analysis, by country
- 5.3. Semisynthetic
 - 5.3.1. Market analysis, by country
- 5.4. Synthetic
 - 5.4.1. Market analysis, by country

CHAPTER 6: EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY



- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. Broad spectrum antibiotics
- 6.2.1. Market analysis, by country
- 6.3. Narrow spectrum antibiotics
 - 6.3.1. Market analysis, by country

CHAPTER 7: EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION

- 7.1. Overview
 - 7.1.1. Market size and forecast
- 7.2. Oral
- 7.2.1. Market analysis, by country
- 7.3. Intravenous
- 7.3.1. Market analysis, by country
- 7.4. Others
- 7.4.1. Market analysis, by country

CHAPTER 8: EUROPEAN ANTIBIOTIC MARKET, BY COUNTRY

- 8.1. Europe
 - 8.1.1. Key market trends, growth factors, and opportunities
 - 8.1.2. Market size and forecast, by country
 - 8.1.2.1. Germany
 - 8.1.2.1.1. Germany antibiotic Market, by drug class
 - 8.1.2.1.2. Germany antibiotic market, by drug origin
 - 8.1.2.1.3. Germany antibiotic market, by spectrum of activity
 - 8.1.2.1.4. Germany antibiotic market, by route of administration
 - 8.1.2.2. France
 - 8.1.2.2.1. France antibiotic market, by drug class
 - 8.1.2.2.2. France antibiotic market, by drug origin
 - 8.1.2.2.3. France antibiotic market, by spectrum of activity
 - 8.1.2.2.4. France antibiotic market, by route of administration
 - 8.1.2.3. UK
 - 8.1.2.3.1. UK antibiotic market, by drug class
 - 8.1.2.3.2. UK antibiotic market, by drug origin
 - 8.1.2.3.3. UK antibiotic market, by spectrum of activity
 - 8.1.2.3.4. UK antibiotic market, by route of administration



- 8.1.2.4. Italy
 - 8.1.2.4.1. Italy antibiotic market, by drug class
 - 8.1.2.4.2. Italy antibiotic market, by drug origin
 - 8.1.2.4.3. Italy antibiotic market, by spectrum of activity
- 8.1.2.4.4. Italy antibiotic market, by route of administration
- 8.1.2.5. Spain
 - 8.1.2.5.1. Spain Antibiotic market, by drug class
 - 8.1.2.5.2. Spain antibiotic market, by drug origin
 - 8.1.2.5.3. Spain antibiotic market, by spectrum of activity
 - 8.1.2.5.4. Spain antibiotic market, by route of administration
- 8.1.2.6. Rest of Europe
 - 8.1.2.6.1. Rest of Europe antibiotic market, by drug class
- 8.1.2.6.2. Rest of Europe antibiotic market, by drug origin
- 8.1.2.6.3. Rest of Europe antibiotic market, by spectrum of activity
- 8.1.2.6.4. Rest of Europe antibiotic market, by route of administration
- 8.1.3. Europe antibiotics market, by drug class
- 8.1.4. Europe antibiotics market, by drug origin
- 8.1.5. Europe antibiotics market, by spectrum of activity
- 8.1.6. Europe antibiotics market, by route of administration

CHAPTER 9: COMPANY PROFILES

- 9.1. ABBOTT LABORATORIES
 - 9.1.1. Company overview
 - 9.1.2. Company snapshot
 - 9.1.3. Operating business segments
 - 9.1.4. Product portfolio
 - 9.1.5. Business performance
- 9.2. ABBVIE INC.(ALLERGEN)
 - 9.2.1. Company overview
 - 9.2.2. Company snapshot
 - 9.2.3. Operating business segments
 - 9.2.4. Product portfolio
 - 9.2.5. Business performance
 - 9.2.6. Key strategic moves and developments
- 9.3. BAYER AG.
 - 9.3.1. Company overview
 - 9.3.2. Company snapshot
 - 9.3.3. Operating business segments



- 9.3.4. Product portfolio
- 9.3.5. Business performance
- 9.4. F. HOFFMANN-LA ROCHE LTD.
 - 9.4.1. Company overview
 - 9.4.2. Company snapshot
 - 9.4.3. Operating business segments
 - 9.4.4. Product portfolio
 - 9.4.5. Business performance
 - 9.4.6. Key strategic moves and developments
- 9.5. GLAXOSMITHKLINE PLC
 - 9.5.1. Company overview
 - 9.5.2. Company snapshot
 - 9.5.3. Operating business segments
 - 9.5.4. Product portfolio
 - 9.5.5. Business performance
- 9.6. MERCK & CO. INC.
 - 9.6.1. Company overview
 - 9.6.2. Company snapshot
 - 9.6.3. Operating business segments
 - 9.6.4. Product portfolio
 - 9.6.5. Business performance
 - 9.6.6. Key strategic moves and developments
- 9.7. VIATRIS INC.(MYLAN)
 - 9.7.1. Company overview
 - 9.7.2. Operating business segments
 - 9.7.3. Product portfolio
 - 9.7.4. Key strategic moves and developments
- 9.8. NOVARTIS INTERNATIONAL AG (SANDOZ)
 - 9.8.1. Company overview
 - 9.8.2. Company snapshot
 - 9.8.3. Operating business segments
 - 9.8.4. Product portfolio
 - 9.8.5. Business performance
 - 9.8.6. Key strategic moves and developments
- 9.9. PFIZER INC.
 - 9.9.1. Company overview
 - 9.9.2. Company snapshot
 - 9.9.3. Operating business segments
 - 9.9.4. Product portfolio



- 9.9.5. Business performance
- 9.10. SANOFI
 - 9.10.1. Company overview
 - 9.10.2. Company snapshot
 - 9.10.3. Operating business segments
 - 9.10.4. Product portfolio
 - 9.10.5. Business performance
 - 9.10.6. Key strategic moves and developments



List Of Tables

LIST OF TABLES

TABLE 01. EUROPEAN ANTIBIOTIC MARKET, BY DRUG CLASS, 2019–2027 (\$MILLION)

TABLE 02. BETA LACTAM & BETA LACTAMASE INHIBITORS, BY TYPE, 2019–2027 (\$MILLION)

TABLE 03. EUROPEAN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027 (\$MILLION)

TABLE 04. EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027 (\$MILLION)

TABLE 05. EUROPEAN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 (\$MILLION)

TABLE 06. EUROPEAN ANTIBIOTIC MARKET REVENUE, BY COUNTRY, 2019–2027(\$MILLION)

TABLE 07. GERMANY STERILE GLOVES MARKET, BY DRUG CLASS, 2019–2027 TABLE 08. GERMANY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027(\$MILLION)

TABLE 09. GERMANY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027(\$MILLION)

TABLE 10. GERMANY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 11. FRANCE ANTIBIOTIC MARKET, BY DRUG CLASS , 2019–2027

TABLE 12. FRANCE ANTIBIOTIC MARKET, BY DRUG ORIGIN,

2019–2027(\$MILLION)

TABLE 13. FRANCE ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027(\$MILLION)

TABLE 14. FRANCE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 15. UK ANTIBIOTIC MARKET, BY DRUG CLASS, 2019–2027

TABLE 16. UK ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027(\$MILLION)

TABLE 17. UK ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY,

2019-2027(\$MILLION)

TABLE 18. UK ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 19. ITALY ANTIBIOTIC MARKET, BY DRUG CLASS, 2019–2027

TABLE 20. ITALY ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027(\$MILLION)

TABLE 21. ITALY ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY,



2019-2027(\$MILLION)

TABLE 22. ITALY ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 23. SPAIN ANTIBIOTIC MARKET, BY DRUG CLASS, 2019-2027

TABLE 24. SPAIN ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027(\$MILLION)

TABLE 25. SPAIN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY,

2019-2027(\$MILLION)

TABLE 26. SPAIN ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 27. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG CLASS, 2019–2027 TABLE 28. REST OF EUROPE ANTIBIOTIC MARKET, BY DRUG ORIGIN, 2019–2027(\$MILLION)

TABLE 29. REST OF EUROPE EUROPEAN ANTIBIOTIC MARKET, BY SPECTRUM OF ACTIVITY, 2019–2027(\$MILLION)

TABLE 30. REST OF EUROPE ANTIBIOTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027(\$MILLION)

TABLE 31. EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS, 2017-2025 (\$MILLION)

TABLE 32. EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 (\$MILLION)

TABLE 33. EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 (\$MILLION)

TABLE 34. EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 (\$MILLION)

TABLE 35. ABBOTT: COMPANY SNAPSHOT

TABLE 36. ABBOTT: OPERATING SEGMENTS

TABLE 37. ABBOTT: PRODUCT PORTFOLIO

TABLE 38. ABBVIE: COMPANY SNAPSHOT

TABLE 39. ABBVIE: OPERATING SEGMENT

TABLE 40. ABBVIE: PRODUCT PORTFOLIO

TABLE 41. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 42. BAYER: COMPANY SNAPSHOT

TABLE 43. BAYER: OPERATING SEGMENTS

TABLE 44. BAYER: PRODUCT PORTFOLIO

TABLE 45. ROCHE: COMPANY SNAPSHOT

TABLE 46. ROCHE: OPERATING SEGMENTS

TABLE 47. ROCHE: PRODUCT PORTFOLIO

TABLE 48. GSK: COMPANY SNAPSHOT

TABLE 49. GSK: OPERATING SEGMENTS



TABLE 50. GSK: PRODUCT PORTFOLIO

TABLE 51. MERCK: COMPANY SNAPSHOT

TABLE 52. MERCK: OPERATING SEGMENTS

TABLE 53. MERCK: PRODUCT PORTFOLIO

TABLE 54. VIATRIS: COMPANY SNAPSHOT

TABLE 55. VIATRIS: OPERATING SEGMENTS

TABLE 56. VIATRIS: PRODUCT PORTFOLIO

TABLE 57. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 58. NOVARTIS: OPERATING SEGMENTS

TABLE 59. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 60. PFIZER: COMPANY SNAPSHOT

TABLE 61. PFIZER: OPERATING SEGMENTS

TABLE 62. PFIZER: PRODUCT PORTFOLIO

TABLE 63. SANOFI: COMPANY SNAPSHOT

TABLE 64. SANOFI: OPERATING SEGMENTS

TABLE 65. SANOFI: PRODUCT PORTFOLIO



List Of Figures

LIST OF FIGURES

FIGURE 01. EUROPEAN ANTIBIOTICS MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS IN THE EUROPEAN ANTIBIOTICS MARKET

FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017-2021*

FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021* (%)

FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017-2021*

FIGURE 06. TOP PLAYER POSITIONING, 2019

FIGURE 07. MODERATE BARGAINING POWER OF BUYERS

FIGURE 08. HIGH BARGAINING POWER OF SUPPLIERS

FIGURE 09. LOW THREAT OF NEW ENTRANTS

FIGURE 10. MODERATE THREAT OF SUBSTITUTION

FIGURE 11. HIGH COMPETITIVE RIVALRY

FIGURE 12. IMPACT ANALYSIS

FIGURE 13. EUROPEAN ANTIBIOTIC MARKET FOR BETA LACTAM AND BETA

LACTAMASE INHIBITORS, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 14. PENICILLIN ANTIBIOTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 15. CEPHALOSPORIN ANTIBIOTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 16. CARBAPENEM ANTIBIOTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 17. MONOBACTAM ANTIBIOTICS MARKET, 2019–2027 (\$MILLION)

FIGURE 18. EUROPEAN ANTIBIOTIC MARKET FOR QUINOLONES, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 19. EUROPEAN ANTIBIOTIC MARKET FOR MACROLIDE, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 20. EUROPEAN ANTIBIOTIC MARKET FOR OTHER, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 21. EUROPEAN NATURAL ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 22. EUROPEAN SEMISYNTHETIC ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 23. EUROPEAN SYNTHETIC INHIBITORS ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 24. EUROPEAN ANTIBIOTIC MARKET FOR BROAD SPECTRUM ANTIBIOTICS, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 25. EUROPEAN ANTIBIOTIC MARKET FOR NARROW SPECTRUM ANTIBIOTICS, BY COUNTRY, 2019–2027 (\$MILLION)



FIGURE 26. EUROPEAN ORAL ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 27. EUROPEAN INTRAVENOUS ANTIBIOTIC MARKET, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 28. EUROPEAN ANTIBIOTIC MARKET FOR OTHERS, BY COUNTRY, 2019–2027 (\$MILLION)

FIGURE 29. GERMANY ANTIBIOTIC MARKET, 2019-2027 (\$MILLION)

FIGURE 30. FRANCE ANTIBIOTIC MARKET, 2019-2027 (\$MILLION)

FIGURE 31. UK ANTIBIOTIC MARKET, 2019-2027 (\$MILLION)

FIGURE 32. ITALY ANTIBIOTIC MARKET FOR ITALY, 2019-2027 (\$MILLION)

FIGURE 33. SPAIN ANTIBIOTIC MARKET, 2019-2027 (\$MILLION)

FIGURE 34. REST OF EUROPE ANTIBIOTIC MARKET, 2019-2027 (\$MILLION)

FIGURE 35. ABBOTT: NET SALES, 2017–2019 (\$MILLION)

FIGURE 36. ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)

FIGURE 37. ABBOTT: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 38. ABBVIE: NET SALES, 2017–2019 (\$MILLION)

FIGURE 39. ABBVIE: REVENUE SHARE BY REGION, 2019(%)

FIGURE 40. BAYER: NET SALES, 2017-2019 (\$MILLION)

FIGURE 41. BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 42. BAYER: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 43. ROCHE: NET SALES, 2018-2020 (\$MILLION)

FIGURE 44. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)

FIGURE 45. ROCHE: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 46. GSK: NET SALES, 2017-2019 (\$MILLION)

FIGURE 47. GSK: REVENUE SHARE BY SEGMENT, 2019 (%)

FIGURE 48. GSK: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 49. MERCK: NET SALES, 2017-2019 (\$MILLION)

FIGURE 50. MERCK: REVENUE SHARE BY SEGMENT, 2019 (%)

FIGURE 51. MERCK: REVENUE SHARE BY REGION, 2019 (%)

FIGURE 52. NOVARTIS: NET SALES, 2018–2020 (\$MILLION)

FIGURE 53. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)

FIGURE 54. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)

FIGURE 55. PFIZER: NET SALES, 2017–2019 (\$MILLION)

FIGURE 56. PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)

FIGURE 57. PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

FIGURE 58. SANOFI: NET SALES, 2017–2019 (\$MILLION)

FIGURE 59. SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)

FIGURE 60. SANOFI: REVENUE SHARE BY REGION, 2019 (%)



I would like to order

Product name: European Antibiotics Market by Drug Class (Beta Lactam & Beta Lactamase, Quinolones,

Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Opportunity Analysis and Industry

Forecast, 2019-2027

Product link: https://marketpublishers.com/r/E47218FB49D6EN.html

Price: US\$ 6,168.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/E47218FB49D6EN.html